Zenas Biopharma Inc (ZBIO) Stock AnalysisZBIOZenas Biopharma Inc

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on development and commercialization of therapies for patients living with autoimmune diseases. It is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, its lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcgRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. Orelabrutinib is a highly selective central nervous system (CNS)-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib's mechanism of action targets pathogenic B cells not only in periphery but also within CNS. Its earlier stage programs include ZB021, an oral small molecule IL-17AA/AF inhibitor; ZB022, a preclinical, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcgRIIb monoclonal antibody. It operates in the Healthcare sector.

Zenas Biopharma Inc is a good buy right now due to its current price of $31.27, which is significantly below the analyst price target of $41 from Citi, indicating a potential upside of 31%. Additionally, the company has a strong cash position of $718.5 million, which supports its operations and upcoming trials. However, the main risk is the negative earnings trend, with a reported EPS of -1.77 in the latest quarter, which reflects ongoing financial challenges.